Principal Financial Group Inc. Sells 256 Shares of STAAR Surgical (NASDAQ:STAA)

Principal Financial Group Inc. decreased its stake in shares of STAAR Surgical (NASDAQ:STAAGet Rating) by 0.1% during the 4th quarter, HoldingsChannel.com reports. The firm owned 341,723 shares of the medical instruments supplier’s stock after selling 256 shares during the quarter. Principal Financial Group Inc.’s holdings in STAAR Surgical were worth $31,199,000 as of its most recent filing with the SEC.

Several other large investors also recently bought and sold shares of the company. Exchange Traded Concepts LLC increased its stake in STAAR Surgical by 127.9% in the fourth quarter. Exchange Traded Concepts LLC now owns 37,041 shares of the medical instruments supplier’s stock valued at $3,382,000 after acquiring an additional 20,787 shares during the period. Allspring Global Investments Holdings LLC bought a new stake in STAAR Surgical in the fourth quarter valued at about $2,460,000. Aegon Asset Management UK PLC increased its stake in STAAR Surgical by 19.0% in the fourth quarter. Aegon Asset Management UK PLC now owns 239,643 shares of the medical instruments supplier’s stock valued at $21,870,000 after acquiring an additional 38,289 shares during the period. AXA S.A. increased its stake in STAAR Surgical by 66.5% in the third quarter. AXA S.A. now owns 86,900 shares of the medical instruments supplier’s stock valued at $11,169,000 after acquiring an additional 34,700 shares during the period. Finally, Jennison Associates LLC bought a new stake in STAAR Surgical in the third quarter valued at about $1,293,000. Institutional investors own 89.93% of the company’s stock.

Shares of STAA stock opened at $58.18 on Friday. STAAR Surgical has a 1 year low of $49.03 and a 1 year high of $163.08. The firm’s 50 day moving average is $66.72 and its 200-day moving average is $81.30. The firm has a market capitalization of $2.78 billion, a price-to-earnings ratio of 100.31 and a beta of 1.18.

STAAR Surgical (NASDAQ:STAAGet Rating) last announced its earnings results on Wednesday, May 4th. The medical instruments supplier reported $0.21 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.10 by $0.11. STAAR Surgical had a net margin of 11.98% and a return on equity of 12.78%. The company had revenue of $63.20 million for the quarter, compared to analyst estimates of $60.53 million. During the same period in the prior year, the business earned $0.13 earnings per share. STAAR Surgical’s quarterly revenue was up 24.5% on a year-over-year basis. Equities research analysts anticipate that STAAR Surgical will post 0.61 earnings per share for the current year.

A number of research firms recently weighed in on STAA. Canaccord Genuity Group upped their target price on shares of STAAR Surgical from $81.00 to $89.00 and gave the company a “buy” rating in a research note on Tuesday, April 26th. Needham & Company LLC reissued a “buy” rating and issued a $87.00 target price on shares of STAAR Surgical in a research note on Tuesday, May 3rd. Zacks Investment Research upgraded shares of STAAR Surgical from a “hold” rating to a “buy” rating and set a $56.00 price target on the stock in a research report on Friday. Benchmark upgraded shares of STAAR Surgical from a “hold” rating to a “buy” rating and set a $97.00 price target on the stock in a research report on Monday, March 28th. Finally, BTIG Research restated a “buy” rating and issued a $98.00 price target on shares of STAAR Surgical in a research report on Saturday, April 23rd. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $95.14.

In related news, VP James E. Francese sold 922 shares of the business’s stock in a transaction that occurred on Monday, March 21st. The shares were sold at an average price of $74.62, for a total transaction of $68,799.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 3.60% of the company’s stock.

About STAAR Surgical (Get Rating)

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.

Featured Articles

Want to see what other hedge funds are holding STAA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for STAAR Surgical (NASDAQ:STAAGet Rating).

Institutional Ownership by Quarter for STAAR Surgical (NASDAQ:STAA)

Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.